Clinical Trials Logo

Neoadjuvant Treatment clinical trials

View clinical trials related to Neoadjuvant Treatment.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04622566 Not yet recruiting - Mucosal Melanoma Clinical Trials

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Start date: December 30, 2020
Phase: Phase 2
Study type: Interventional

This study is a randomized ,single center clinical study which is designed to investigate whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent survival in resectable mucosal melanoma. All the eligible patients were assigned to receive Lenvatinib once a day (QD) for 6 weeks plus pembrolizumab on Day 1 of each 21-day cycle (Q3W) concurrently on days 1 and 22, followed by surgery and 18 cycles of Pembrolizumab 200mg q3w of adjuvant phase.